Europe Respiratory Inhalers Market Report and Forecast 2024-2032

Europe Respiratory Inhalers Market Outlook

The global respiratory inhalers market size was valued at USD 33.5 billion in 2023, with Europe holding a significant market share. It is driven by the increasing number of respiratory disease cases in the region. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, and attain a value of USD 53.9 billion by 2032.

Key Takeaways

• In March 2024, Boehringer Ingelheim made an investment to improve the affordability and access of inhaler products for COPD and asthma patients by capping out-of-pocket cost at USD 35 per month. Such initiatives, aimed at providing affordable resources to the consumers is one of the notable Europe respiratory inhalers market trends.

• In March 2023, Teva Pharmaceuticals collaborated with Rimidi, for a respiratory patient monitoring program. Increasing collaborations and partnerships are poised to drive the market growth during the forecast period.

• The market is witnessing an influx of new and innovative devices. In July 2023, Lupin unit launched pressurized metered dose inhalers in Germany.

Europe Respiratory Inhalers Market Analysis

Respiratory inhalers are used to breathe in medication in case of chronic lung diseases. Air pollution is one of the major reasons for the increase of respiratory diseases. The Organization for Economic Co-operation and Development (OECD) projects the global greenhouse gas emissions to increase by 50%, majorly due to 70% increase in energy related CO2 emissions. As a result, respiratory diseases such as asthma, COPD and bronchitis are projected to increase in the forecast period, fuelling the Europe respiratory inhalers market demand significantly.

According to World Health Organization (WHO), asthma is a noncommunicable and most chronic disease among children. Medication taken via inhalation can curb the symptoms and allow the patient to live a normal life. Consequently, the application of inhalers to provide effective solutions to patients belonging to diverse age groups is likely to drive the Europe respiratory inhalers market growth in the forecast period.
The market is expanding with increasing collaborations in the region. In January 2024, Inhalation Sciences and Actarmo, a Germany based company entered a collaboration for respiratory drug development services. The deal between the two organizations comprises of preclinical in vitro and in vivo pharmacokinetics studies, involving testing of devices and the complete development of inhalational combination assets. In July 2023, Hormosan Pharma GmbH, a subsidiary of Lipun introduced pressurized metered dose inhalers, Luforbec for the treatment of COPD and asthma in Germany. Luforbec is a combination of corticosteroid and long-acting beta 2 agonist. Increasing incidence of strategic mergers and collaborations aimed at improving patient outcomes is likely to augment Europe respiratory inhalers market share in the coming years.

Few of the inhalers in the European region are Neovent, Salamol, Ventolin, and Easyhaler among Others. The market share is also fuelled by the advent of smart and digital inhalers, along with the development of eco-friendly solutions. In March 2023, Teva Pharmaceuticals partnered with Rimidi to launch a respiratory patient monitoring program with the help of Teva’s Digihaler System. Increasing public awareness around the early diagnosis for respiratory conditions, along with campaigns around using inhalers with ease are amongst major market trends.

Europe Respiratory Inhalers Market Segmentation

The report offers a detailed analysis of the market based on the following segments:
 

Europe Respiratory Inhalers Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AstraZeneca Plc

• Beximco Pharmaceuticals Ltd.

• Boehringer Ingelheim International GmbH

• Cipla Ltd

• GSK Plc

• Koninklijke Philips NV

• OMRON Corp

• PARI Respiratory Equipment, Inc

• OPKO Health, Inc

• Teva Pharmaceutical Industries Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report